Analyse van uitgeademde lucht om de respons op behandeling met mepolizumab te voorspellen in patiënten met ersntig astma.
Recruiting
- Conditions
- Severe Asthma
- Registration Number
- NL-OMON26797
- Lead Sponsor
- Amsterdam UMC, University of Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 250
Inclusion Criteria
Adult patients with severe refractory eosinophilic asthma who are treated with Mepolizumab.
-Poor asthma control or frequent (≥2 per year) exacerbations, despite high-intensity treatment while alternative diagnoses have been excluded, comorbidities are treated and compliance has been checked.
Exclusion Criteria
- Alcohol use <12 hours prior to measurement.
- Unwillingness or inability to comply with the study protocol for any other reason.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - eNose ‘Breathprints’ (signature of mixtures of volatile organic compounds (VOCs) in exhaled breath)
- Secondary Outcome Measures
Name Time Method -Absence of exacerbations during 12 months after initiation of mepolizumab therapy. <br /><br>-Improvement of Asthma Control Questionnaire (ACQ)-score by 0.5 points over 6 months. <br /><br>-Decrease of oral corticosteroid (OCS) use by 50% after 12 months. <br /><br>-Any switch of biological therapy.<br>